Zobrazeno 1 - 10
of 50
pro vyhledávání: '"C. K. Buckner"'
Autor:
Russell C. Mauger, Terrance G. Ulatowski, David Aharony, Robert T. Jacobs, C. K. Buckner, Ashok B. Shenvi
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 8:1935-1940
A series of 4-alkylpiperidine derivatives related to the potent neurokinin-2 (NK2) receptor antagonist SR-48968 (1) is described. Simple aliphatic derivatives were found to be poorly active, but appropriate placement of an alcohol functional group af
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2426db85fd98af51dfc7c4f118529f5
https://doi.org/10.1016/s0960-894x(98)00037-7
https://doi.org/10.1016/s0960-894x(98)00037-7
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 5:2879-2884
Modification of the heterocyclic nucleus of a lead pyrrolopyrimidine (1) found to be active as an antagonist at the neurokinin-2 (NK2) receptor is described. Compounds based on the purine nucleus (3) were found to be particularly interesting, and wer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e02d37f40377abb9fd3a9ec8717a2d2
https://doi.org/10.1016/0960-894x(95)00502-k
https://doi.org/10.1016/0960-894x(95)00502-k
Autor:
Edward J. Kusner, Donna M. Dea, Rebecca L. Marks, R D Krell, C. K. Buckner, Christopher J. DeHaas
Publikováno v:
European Journal of Pharmacology. 257:285-292
The non-redox 5-lipoxygenase inhibitor Zeneca ZD2138 (6-[(3-fluoro-5-[4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl])phenoxy- methyl]-1-methyl-2-quinolone) was evaluated for its ability to inhibit antigen-induced leukotriene release from guinea-pig lung
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfa7212b7ed5988b9d94b2dde7e7553b
https://doi.org/10.1016/0014-2999(94)90140-6
https://doi.org/10.1016/0014-2999(94)90140-6
Autor:
C. K. Buckner, Edward Vacek, Edward J. Kusner, David Aharony, Laura A. Cronk, Peter R. Bernstein, L. F. Newcomb, Robert T. Jacobs
Publikováno v:
ChemInform. 25
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25c9406b72ffb8d31b6d6063c17d5cb9
https://doi.org/10.1002/chin.199436146
https://doi.org/10.1002/chin.199436146
Publikováno v:
ChemInform. 27
Modification of the heterocyclic nucleus of a lead pyrrolopyrimidine (1) found to be active as an antagonist at the neurokinin-2 (NK2) receptor is described. Compounds based on the purine nucleus (3) were found to be particularly interesting, and wer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2e36879cced62884eeea75baec188d9
https://doi.org/10.1002/chin.199614175
https://doi.org/10.1002/chin.199614175
Autor:
Terrance G. Ulatowski, Ashok B. Shenvi, Russell C. Mauger, David Aharony, C. K. Buckner, Robert T. Jacobs
Publikováno v:
ChemInform. 29
A series of 4-alkylpiperidine derivatives related to the potent neurokinin-2 (NK2) receptor antagonist SR-48968 (1) is described. Simple aliphatic derivatives were found to be poorly active, but appropriate placement of an alcohol functional group af
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::111e391689cebb6214210a02ca1ced57
https://doi.org/10.1002/chin.199847289
https://doi.org/10.1002/chin.199847289
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 292(1)
The effect of selective tachykinin receptor agonists and antagonists on human isolated intralobar pulmonary arterial rings was investigated. Neither Substance P (SP) nor neurokinin A (NKA) contracted the arteries. Both of these agonists, however, wer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9de937799e0a6b7c74d1b01354c8ba14
https://pubmed.ncbi.nlm.nih.gov/10604965
https://pubmed.ncbi.nlm.nih.gov/10604965
Autor:
D, Aharony, C K, Buckner, J L, Ellis, S V, Ghanekar, A, Graham, J S, Kays, J, Little, S, Meeker, S C, Miller, B J, Undem
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 274(3)
We examined the pharmacology of ZM253,270 and two representative examples of the pyrrolopyrimidines, a new class of nonpeptide, NK-2 receptor (NK-2R) antagonists. ZM253,270 competitively inhibited [3H]NKA binding to native or cloned NK-2R from hamste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::53af57f22932db570fe1cd0baa94823b
https://pubmed.ncbi.nlm.nih.gov/7562491
https://pubmed.ncbi.nlm.nih.gov/7562491
Autor:
C. K. Buckner, David J. Lengel, Edward J. Kusner, Christopher J. DeHaas, Joseph C. Williams, R D Krell
Publikováno v:
Annals of the New York Academy of Sciences. 744
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fd1a77103979d46ff9848c5f57f1b31
https://pubmed.ncbi.nlm.nih.gov/7825851
https://pubmed.ncbi.nlm.nih.gov/7825851
Autor:
C K, Buckner, N, Liberati, D, Dea, D, Lengel, C, Stinson-Fisher, J, Campbell, S, Miller, A, Shenvi, R D, Krell
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 267(3)
This study has examined the abilities of (+/-)-CP96345 and (+/-)-SR48968, nonpeptide antagonists selective for the tachykinin NK1 and NK2 receptors, respectively, to block bronchoconstriction caused by intravenous administration of direct-acting rece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b051bed9040deb39010c23b13d4c113e
https://pubmed.ncbi.nlm.nih.gov/8263778
https://pubmed.ncbi.nlm.nih.gov/8263778